Positive Phase II data with Apogenix's brain cancer drug
This article was originally published in Scrip
Executive Summary
Apogenix has reported that a Phase II trial investigating its lead product APG101, a CD95 ligand (CD95L) inhibitor, has met the primary endpoint in the second-line treatment of glioblastoma multiforme (GBM), after a six-month follow up of the last patient treated.